ARDS is a life-threatening impairment of lung function and oxygenation resulting from direct injury or secondary trauma or infective process and is prevalent in approx. 10% of patients in intensive care units worldwide The pathology of ARDS shows diffuse alveolar damage resulting in survivors having ongoing functional or physiological sequelae resulting in a high mortality rate with few effective therapeutic modalities (lung protective ventilation). There is no current pharmacological treatment of ARDS. Personalised lung-protective mechanical ventilation reduces mortality and has become the mainstay of treatment in ARDS. Treatment costs are estimated at US $139K after 1 year and US $210K after 2 years and the global device market is expected to reach $19.5 billion by 2029, expanding at a CAGR of 7.3%.

Heparin Therapeutics will be commencing patient enrolment for its Phase 1 study of HT231 in healthy volunteers in Q1 2026 with a Phase 2 stand alone multi-centre adaptive randomized study in ca. 100 patients at risk of ARDS and receiving supplemental oxygen planed to commence a year later.

To find out about our other products in development please contact us directly.